Evolutec Group Report issue

For profit Phase 2
Founded: London United Kingdom (2001)
Status: Defunct (2009)

Organization Overview

First Clinical Trial
2005
NCT00247520
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Alternative names

Evolutec Group plc

Active Ingredients

Drugs in Phase 2 Trials (2)

prednisone (meticorten) (1 trial)

rev131 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Capsule Opacification (Phase 2)

Cataract (Phase 2)

Inflammation (Phase 2)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Rhinitis, Allergic, Seasonal (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2